13F
← All fund report cards

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

13F equity value
$184.8B
Positions
1,810
Top 10 concentration
26.2%
Quarters / total new picks
32 / 7,447
13F equity value over time
$0M$92B$185B2017201820192020202120222023202420252026

"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.

Not significant Verdict

13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.

We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 32 quarters, returned +2.1% per quarter — versus +2.7% per quarter from simply owning every 13F stock. It beat that baseline in only 40.6% of quarters (excess t = -0.08, not statistically significant). Its filings tell you what it bought — not what you should buy.

Avg 2Q excess
-0.1%
t-stat
-0.08
Quarterly win rate
41%
Annualized excess
-2.2%
$1 → follow vs universe
$1.77 vs $2.09
Cumulative return: $1 invested in new picks vs universe
1.00 20180331: universe 1.04120180630: universe 0.95920180930: universe 1.00320181231: universe 0.99220190331: universe 0.97520190630: universe 1.04820190930: universe 1.12720191231: universe 0.90920200331: universe 1.09620200630: universe 1.21120200930: universe 1.48520201231: universe 1.55320210331: universe 1.56620210630: universe 1.69220210930: universe 1.51920211231: universe 1.29220220331: universe 1.38720220630: universe 1.28520220930: universe 1.38120221231: universe 1.28220230331: universe 1.35120230630: universe 1.30320230930: universe 1.47920231231: universe 1.54520240331: universe 1.58020240630: universe 1.72320240930: universe 1.70820241231: universe 1.59420250331: universe 1.73820250630: universe 1.79320250930: universe 2.01620251231: universe 2.085 20180331: follow 1.04420180630: follow 0.97520180930: follow 1.00520181231: follow 0.95520190331: follow 0.93320190630: follow 1.02220190930: follow 1.07920191231: follow 0.84920200331: follow 1.00720200630: follow 1.10920200930: follow 1.30420201231: follow 1.28220210331: follow 1.30620210630: follow 1.37620210930: follow 1.29520211231: follow 1.18220220331: follow 1.21820220630: follow 1.11920220930: follow 1.21820221231: follow 1.15620230331: follow 1.20020230630: follow 1.19120230930: follow 1.28320231231: follow 1.33920240331: follow 1.37520240630: follow 1.50420240930: follow 1.48420241231: follow 1.35620250331: follow 1.43420250630: follow 1.51220250930: follow 1.75120251231: follow 1.769 0.78 1.52 2.25 20182019202020212022202320242025 Follow Universe

Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)

Listed as facts. See the verdict above before treating this as signal.

Top 20 holdings of 1810 · 2026 Q1

Ticker Value Weight QoQ
MSFT $9.0B
4.9%
ADD
AMZN $6.8B
3.7%
ADD
AVGO $5.8B
3.1%
ADD
NVDA $5.5B
3.0%
ADD
AAPL $4.9B
2.7%
ADD
GOOGL $4.9B
2.6%
ADD
GOOG $4.2B
2.3%
ADD
LRCX $2.8B
1.5%
HOLD
CRM $2.4B
1.3%
ADD
ASML $2.2B
1.2%
ADD
B $1.9B
1.1%
HOLD
MA $1.8B
1.0%
ADD
SNDK $1.8B
1.0%
TRIM
SU $1.7B
0.9%
ADD
INTU $1.7B
0.9%
ADD
ADBE $1.7B
0.9%
ADD
PLTR $1.5B
0.8%
ADD
APH $1.5B
0.8%
HOLD
CNQ $1.4B
0.8%
NEW
DIS $1.4B
0.7%
ADD

QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.

Listed as facts. See the verdict above before treating this as signal.

New positions in 2026 Q1

Method & Limitations

Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.